Fig. 3: Juxtaposition of favorable and unfavorable prognostic biomarkers offers precise overall survival stratification.
From: Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark
a Venn diagrams showing the distribution of patients with kidney renal papillary cell carcinoma (KIRP) (left) and kidney renal clear cell carcinoma KIRC (right) based on expression of the top favorable (labeled in Supplementary Fig. S4e) and the top unfavorable (labeled in Fig. 2e) combination prognostic markers on RNA-seq from tumor samples. b Kaplan–Meier (KM) overall survival curves for 4 subgroups of KIRP or KIRC patients whose tumors express indicated combination of prognostic biomarkers. The four subgroups are highlighted with a bold font in a. Hazard ratio (HR) and logrank test p-values denote comparisons with the lines in red. ns not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. c Plots showing the fraction of KIRP (left) and KIRC (right) tumors which have alterations (methylation or copy number loss) in CDKN2A63 in each group. Source data are provided as a Source Data file.
